zanubrutinib,zandelisib
beigene,mei,kyowa kirin
['mantle,(-dismantle)', 'zandelisib', 'follicular', 'zanu ', 'lymphoma', 'lymsm', 'emergent ', 'nordic']
zanu + intermittent zandelisib dosing for r/r fl+mcl. orr 87% fl, 72% mcl. nice pfs in fl, less in mcl. really want to see pro data re: aes. less promising given fda odac. #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????